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Objective: To test effectiveness of the Early Detection, 
Intervention, and Prevention of Psychosis Program in pre-
venting the onset of severe psychosis and improving func-
tioning in a national sample of at-risk youth. Methods: In a 
risk-based allocation study design, 337 youth (age 12–25) at 
risk of psychosis were assigned to treatment groups based on 
severity of positive symptoms. Those at clinically higher risk 
(CHR) or having an early first episode of psychosis (EFEP) 
were assigned to receive Family-aided Assertive Community 
Treatment (FACT); those at clinically lower risk (CLR) 
were assigned to receive community care. Between-groups 
differences on outcome variables were adjusted statistically 
according to regression-discontinuity procedures and evalu-
ated using the Global Test Procedure that combined all 
symptom and functional measures. Results: A total of 337 
young people (mean age: 16.6) were assigned to the treat-
ment group (CHR + EFEP, n = 250) or comparison group 
(CLR, n = 87). On the primary variable, positive symptoms, 
after 2 years FACT, were superior to community care (2 df, 
p < .0001) for both CHR (p = .0034) and EFEP (p < .0001) 
subgroups. Rates of conversion (6.3% CHR vs 2.3% CLR) 
and first negative event (25% CHR vs 22% CLR) were low 
but did not differ. FACT was superior in the Global Test 
(p =  .0007; p =  .024 for CHR and p =  .0002 for EFEP, 
vs CLR) and in improvement in participation in work and 
school (p = .025). Conclusion: FACT is effective in improv-
ing positive, negative, disorganized and general symptoms, 
Global Assessment of Functioning, work and school partici-
pation and global outcome in youth at risk for, or experienc-
ing very early, psychosis.
Key words: schizophrenia/family psychoeducation/ 
multifamily group/supported education/supported 
employment/assertive community treatment
Introduction
Schizophrenia and the psychotic forms of the major 
mood disorders are debilitating, exacting a significant 
toll on patients, families, and society. Psychoses rank in 
the top 3 most disabling conditions worldwide.1,2 It is 
estimated that 2%–3% of the adult population develops 
a psychosis, constituting a major burden to public health. 
These are devastating disorders for families, who often 
assume major caretaking and psychological burdens. It 
has been estimated that the annual total costs are $61 bil-
lion for schizophrenia alone.3
Recent evidence suggests that early intervention 
prior to onset of  a psychotic disorder may delay or 
prevent onset of  frank psychosis and the deteriora-
tion in functioning so common in the psychoses.4 
A  recent comprehensive meta-analysis reported that 
the overall risk ratio in 9 preventive clinical trials was 
0.34.5 Research to date has built on the observation 
that duration of  untreated psychosis predicts later 
outcomes.6 Even when the individual already meets 
criteria for a current psychotic episode, intervention 
shortly after onset may improve outcomes by initiat-
ing treatment when the individual is more sensitive to 
treatment.7,8 Without treatment, many of  those found 
to be at risk function poorly, even in the absence of  a 
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psychotic episode.9 For those at risk, early interven-
tion has the potential to prevent onset of  a full psy-
chotic disorder; treat the impaired cognitive, social, 
and occupational functioning already present; and 
alleviate family distress.10–12
One example of these indicated prevention approaches, 
the Portland Identification and Early Referral (PIER) 
program, is a population-wide system of early detection 
and preventive intervention in Greater Portland, ME.13 It 
includes extensive community education about the early 
signs of psychosis and the potential benefits of early 
treatment. Families and young people who meet criteria 
for high risk of onset of psychosis receive Family-aided 
Assertive Community Treatment (FACT), a package of 
interventions consisting of psychoeducational multifam-
ily group (PMFG) therapy, elements of assertive commu-
nity treatment, supported education and employment, 
and psychotropic medication.13–15 Family intervention 
is the principal treatment component, based on the evi-
dence for its efficacy in schizophrenia and first episode 
and prodromal psychosis.16–19
The Early Detection and Intervention for the 
Prevention of  Psychosis Program (EDIPPP) was under-
taken to build on these findings by testing the effective-
ness of  the PIER approach across the United States in 
a large, ethnically, and geographically diverse popula-
tion, in 6 typical mental health agencies and settings. 
The goal was to evaluate whether early intervention, ie, 
prior to onset of  psychosis, with young people at clini-
cal high risk could delay or prevent the development 
of  frank psychosis and reduce functional impairment, 
in typical and diverse populations and clinical settings.
Methods
Details of the study design, implementation, assessment, 
psychosocial and pharmacological treatments, methods, 
and characteristics of the sample have been reported 
elsewhere.20
Early Identification
A community outreach and education program targeted 
to teachers, school, and college counselors; nurses and 
social workers; family and pediatric physicians; and psy-
chiatric practitioners, clinics, and hospitals was under-
taken at each site. The objectives were to: (a) increase 
knowledge of early warning signs for psychotic disorders, 
(b) increase appropriate referrals of youth at risk, (c) cre-
ate and educate a system of professional and community 
member early identifiers, and (d) decrease barriers to early 
identification, including stigma.13,21–23 The 6 study sites 
conducted extensive, ongoing community and profes-
sional education within their respective catchment areas, 
beginning in July, 2007. Enrollment began in September, 
2007 and continued throughout the study period, ceasing 
on June 1, 2010.
Setting
In addition to the Greater Portland, ME, the other 5 sites 
were: Sacramento, CA; Ypsilanti, MI; Glen Oaks, NY; 
Salem, OR; and Albuquerque, NM.
Inclusion and Exclusion Criteria
Both positive and negative symptoms of psychotic dis-
orders warranted referral for an assessment. All referrals 
of adolescents and young adults living in a site’s catch-
ment area were considered for eligibility. A phone screen-
ing interview with a trained referrer assessed whether 
eligibility was likely. If  so, the young person and fam-
ily were offered a full research and clinical assessment, 
which included the Structured Interview for Prodromal 
Syndromes (SIPS),24 a component of which is the Scale 
of Prodromal Symptoms (SOPS) scale.21,22 Inclusion cri-
teria for the full study sample were established to recruit 
clinically lower risk (CLR), clinically higher risk (CHR), 
and very early first-episode psychosis (EFEP) partici-
pants. Those criteria were: (a) age 12–25, (b) living in the 
site’s defined catchment area, and (c) having at least a 1 
on any Positive Symptom Scale or a 3 on any Negative 
Symptom Scale of the SOPS. For instance, for Unusual 
Thought Content (the prodromal version of delusional 
ideas), a “1” would be rated if  the person experienced 
“mind tricks” or a “sense that something is different.” At 
a level “3” on Avolition on the Negative Symptoms Scale, 
the person would be manifesting “low levels of motiva-
tion to participate in goal-directed activities” or “impair-
ment in task initiation and/or persistence.” Youth having 
a current frank psychotic episode (a 6 on any Positive 
Symptom Scale for longer than 30 consecutive days) were 
excluded from the study and assisted in finding other 
treatment. Other exclusion criteria included: (a) a prior 
episode of psychosis or having received antipsychotic 
medication for 30 days or more at a dosage appropriate 
to treat a psychotic episode, (b) IQ less than 70, (c) per-
manent residence outside the catchment area, (d) not an 
English speaker or neither parent is an English speaker, 
(e) currently a prisoner in the criminal justice system, and 
(f) psychotic symptoms due to an acute toxic or medical 
etiology.
Intake and Follow-up Assessments
Independent research interviewers conducted all base-
line and outcome assessments and were kept blind to 
treatment assignment. In addition to the SIPS interview, 
baseline assessment included the Global Assessment 
of  Functioning (GAF)23 and the Structured Clinical 
Interview for DSM-IV Axis I  Disorders, Clinician 
Version (SCID-I/CV).25 Although onset of  psychosis 
(ie, conversion) has been the focus of  previous preven-
tion studies, an additional emphasis of  EDIPPP was 
on role and social functional outcomes.13,26 Measures 
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included the Global Functioning: Social and Global 
Functioning: Role Scales (GF:S, GF:R)27 and the 
Heinrichs Quality of  Life Scale (QLS).28 The Premorbid 
Adjustment Scale29 and family history of  mental disor-
der (Family History-Epidemiological)30 were also col-
lected at baseline. SIPS, GAF, GF:R and GF:S, and the 
Heinrichs QLS assessments were repeated at the 6-, 12-, 
and 24-month points; the SCID was repeated at the 
24-month point.
Key outcome variables included (a) conversion to 
psychosis, (b) positive and negative symptoms, (c) first 
occurrence of a negative event, and (d) changes in social 
and occupational functioning. Conversion to psycho-
sis was defined according to the Presence of Psychosis 
Scale (POPS) criteria: sustaining any 6 on the Positive 
Symptom Scale for 4 or more days per week, at least 1 
hour per day for at least 30 days, or demonstrating seri-
ously disorganized or dangerous behavior.21 Negative 
events included conversion, relapse, psychiatric hospital-
ization, incarceration, suicide attempt, completed suicide, 
severe self-harm, rape, or assault.
Design
The effectiveness of EDIPPP’s clinical intervention was 
tested using a Risk-based Allocation Design (also known 
as Regression-Discontinuity).31,32 The range of symptoms 
among study subjects was reflected in 3 clinically mean-
ingful subgroups: CLR, CHR, and EFEP. A  person’s 
baseline score on the primary outcome variable, psychotic 
symptoms, determined his or her treatment group. A par-
ticipant was assigned to the treatment group if  the sum 
Positive Symptoms score (P-score) was 7 or higher (CHR 
and EFEP subgroups), while those below that threshold 
were assigned to the CLR comparison group. The EFEP 
group was defined as those participants with psychotic 
symptoms of 30 days or less duration. A P-score of 7 was 
selected as the threshold to maximize the probability that 
a participant at high risk for psychosis would be assigned 
to the treatment group. Among sum scores of 6–11, 7 had 
a high sensitivity score of 0.91 and acceptable specific-
ity of 0.78, the dependent variable being prodromal vs 
not prodromal by SOPS criteria. Adjusting statistically 
for baseline P-score removes the bias of initial differ-
ences between the treatment and comparison groups (see 
McFarlane et al20 and the supplementary data for fuller 
explanation of methods and assumptions). Consequently, 
significant postintervention differences between groups 
can be attributed to the intervention itself, where the 
intervention effect is represented by a discontinuity in the 
regression lines at the cut-point. Compared with random-
ized assignment, this design has the ethical advantage that 
those who most need treatment are assigned to the treat-
ment condition, while participants at lower risk may be 
protected from the adverse effects of unnecessary treat-
ment. Youth who were assigned to the CLR comparison 
group were considered to be at lower risk for developing 
psychosis, but not risk free.
Treatment
Both the CHR and EFEP subgroups were provided 
FACT, regardless of level of psychosis (see supplemen-
tary data for additional detail on FACT).14,15,24 Regarding 
psychotropic medication, if  attenuated positive symp-
toms were present or emerged at or above a level of “4” on 
the Positive Symptom Scale of the SIPS, aripiprazole was 
offered within a dosage range of 1–15 mg. If  that was not 
tolerated, another antipsychotic medication was offered; 
antipsychotic medications were discontinued altogether 
if  severe side effects persisted. Mood-stabilizing, antide-
pressant, and anxiolytic medications were provided for 
specific symptoms of major mood or anxiety disorders, 
using current clinical practice guidelines. The principal 
modification to FACT to accommodate younger patients 
was to differentiate multifamily groups by age. Thus, 12- 
to 15-year olds were assigned to a “younger” multifamily 
group and those in the 17–25 range to an “older” group, 
while those in the 15–17 range were assigned on the basis 
of developmental age and family preferences.
The CLR group received monthly monitoring through 
a phone assessment conducted by a care manager. They 
could choose, but were neither encouraged nor assisted, 
to obtain treatment elsewhere in the community. As a 
subject protection measure, markedly increasing psy-
chotic symptoms were treated with antipsychotic medica-
tion by the EDIPPP team until symptoms resolved.
Reliability Assessment, Blinding, and Treatment 
Fidelity
Reliability on the SOPS symptom scores, POPS, Heinrichs 
QLS, GF:S, and GF:R scales was measured among 37 
raters’ scores, compared with criterion scoring by an 
experienced psychiatric researcher.20
The interviewers were highly reliable: overall intra-
class  correlation for ratings of positive symptoms was 
.91, and the cross-site range was from .82 to .94. The 
reliability of the POPS criterion rating was also good 
(κ  =  0.68; percent agreement  =  93%). Possible bias of 
interviewers was assessed at each assessment point and 
analyzed to determine whether raters from a given site 
evaluated the patient differently than fully blinded raters 
from other sites. Among 35 pairs of ratings, correlations 
ranged from .90 for positive symptoms to .71 for disorga-
nized symptoms and GAF; all were significant (p < .001). 
We concluded that the blinding process was adequate to 
prevent biased ratings.
After initial training and during ongoing supervision, 
clinicians’ fidelity to the PMFG treatment component was 
assessed using the Competency Checklist.33 This measure 
had been validated in a trial of the multifamily psycho-
education modality.33 Fidelity was high (mean 85.6% of 
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checklist items, ranging from 82% to 90% across sites and 
increasing from 80% to 92% during the study) and above 
the threshold found to predict treatment effects.33
Analysis
All statistical tests were conducted on an “as assigned” 
basis. Two types of outcomes analysis were conducted: 
the effect of treatment on (a) time to first negative event 
and (b) clinical symptoms and psychosocial function-
ing. A  preliminary test showed that the regression-dis-
continuity model fit significantly better when the CHR 
and EFEP subgroups were distinguished as 2 groups as 
opposed to pooled. Therefore, in all subsequent analyses, 
we used 2 df tests of significance for FACT intervention 
and included 2 indicator variables for CHR and EFEP 
subgroups. The effect of treatment on the time to first 
negative event was analyzed using Cox regression analy-
sis34 and hazard ratios (HRs) are reported with 95% CIs. 
The Cox proportional hazards assumption was tested for 
each model variable (baseline P-score, CHR, and EFEP 
indicators) and found acceptable (p = .0945, 0.1710, and 
0.8816, respectively). The effect of treatment on symptom 
and functioning outcomes was analyzed using mixed-
effects regression analysis as the primary and the Global 
Test Procedure (GTP) as a secondary analysis.35,36 In the 
primary analysis, the main effects for the 2 intervention-
group indicators (CHR and EFEP) tested the difference 
between those groups and the CLR comparison group, 
with emphasis on the 24-month outcome as the primary 
endpoint. Indicator variables for time points at which 
the outcome was observed were included in the model to 
allow estimation of the trajectory of response at 6, 12, 
and 24 months and to allow for a nonlinear trajectory; 
and visit-by-subgroup interaction terms were included in 
the model to allow for arbitrary changes in the interven-
tion effect over these time points. The random intercept 
included in the mixed model allows for subject-to- subject 
variation in the overall level of the outcome variable 
across the follow-up period, though the trajectories 
through time were considered nonrandom and estimated 
through the fixed-effect time-point indicators.
The intervention-group assignment variable (the sum 
P-score) was entered as a covariate in all analyses, as is 
necessary in a regression-discontinuity analysis. For analy-
ses of outcome variables other than the positive symptom 
scale, the baseline value of each of those variables was also 
entered as a covariate. Study site indicators were included 
to adjust for variations in outcomes by geographic loca-
tion. The assumptions of parallel and linear regressions 
were tested and found acceptable (p = .64 for group-by-P-
score interactions and p = .63 for quadratic P-score term). 
Previous analyses20 had shown that after adjustment for 
the baseline value of the positive symptom variable, mean 
values of the other measures at baseline were essentially 
equivalent, demonstrating the ability of the regression 
discontinuity analysis subsequently to furnish unbiased esti-
mates of treatment effects. For descriptive purposes only, 
we also report unadjusted mean change scores between 
baseline and 24 months with corresponding t tests.
The proportion of subjects who increased their partici-
pation in work or school from baseline to 24 months—(a) 
from participation in neither work nor school to either 
work or school, or both work and school or (b) from 
either work or school to both work and school—was 
compared using Fisher’s exact test with 95% CIs for the 
OR comparing the CLR group with the combined CHR 
+ EFEP groups.
A GTP was used to assess whether information from 
all 10 variables (SIPS, GAF, etc.) supports a positive 
intervention effect across the battery of  outcome mea-
sures. The procedure used a fixed-effects model and 
estimated a single coefficient representing the treatment 
effect across the entire battery, while allowing other 
terms such as intercepts and time-point effects to vary 
from one outcome measure to another. The baseline 
assignment variable was included in all outcome mea-
sure equations to reflect the regression-discontinuity 
design. No adjustment for multiple comparisons due 
to the several measures considered is required because 
there is only a single intervention effect measured (one 
for each intervention subgroup); ie, the model assumes 
a single, constant treatment effect for each measure. 
The 10 measures were linearly transformed to a scale of 
1–10 with reversal of  direction for the 4 SIPS variables 
in order to put each outcome measure on a uniform 
scale in which the assumption of  a constant interven-
tion effect is plausible. The intervention effects for the 
CHR and EFEP subgroups (each vs the CLR group) 
were estimated assuming an unstructured covariance 
matrix in both variable space (10 measures) and time (3 
time points). Details of  the GTP model are contained in 
the supplementary data.
Results
Referrals and Participant Sample
Across sites, 520 cases were recommended for orienta-
tion, and 392 (75.4%) signed informed consent/assent 
and were oriented and assessed (figure 1). Of these, 337 
(86.0%) met inclusion criteria and were allocated to treat-
ment, 87 (25.8%) to the CLR comparison group, and 250 
(74.2%) to the CHR + EFEP treatment group. Within 
the treatment group, 205 cases (82%) were designated as 
the CHR subgroup; 45 (18%) were found to have an early 
psychosis and were designated as the EFEP subgroup.
The study sample as a whole matched national racial, 
ethnic, and socioeconomic distributions rather closely 
(table 1).
Fifteen percent of the population was of Hispanic 
origin (compared with 15.1% nationally), while 9% was 
African-American (compared with 12.8% nationally): 
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males predominated, 60%–40%. The mean age for the 
CHR and EFEP subsamples—16.4 and 17.9  years, 
respectively—was in mid-adolescence, much younger 
than the usual age of onset for psychoses, usually found 
to be in the range of 20–25 years.37 The between-groups 
differences in positive symptom scores reflected the 
expected levels, given that the patients were assigned to 
groups on the basis of this score. Although mean baseline 
GAF scores and diagnoses were also distributed across 
groups as expected, social and role functioning scores 
(ie, GF:R, GF:S, and QLS) were not, being nearly equal 
for all 3 conditions (see table 2). Eighty-four percent of 
the CHR and 78% of the CLR groups had current Axis 
I disorders; 49% of the CHR group had a major mood 
disorder, including 6% with bipolar disorder, and 42% 
had an anxiety disorder. Equal proportions of the CHR 
and CLR comparison subsamples had been hospitalized 
(26% vs 24%), received prior outpatient treatment (75% 
vs 72%), and had prior exposure to antipsychotic drugs 
(31% vs 27%). Eighty-four percent of the sample was in 
school or working, and this did not differ across all 3 
assigned subgroups.
After treatment assignment at baseline, 76% of the 
CLR group sought and received a variety of treatments 
in the community, ie, not provided by the study clinicians. 
Sixty-three percent received individual therapy, 36% fam-
ily therapy, 37% supported employment/education, 30% 
antipsychotic medication, 47% antidepressants, and 4.8% 
mood stabilizers. However, PMFG treatment was only 
received by the FACT cohort. Eighty percent of the CHR 
and 89% of the EFEP subgroups received the PMFG 
component of the FACT intervention.
Symptom Outcomes
For the primary outcome variable, positive symptoms, 
FACT was superior, for both CHR and EFEP subgroups, 
to the CLR comparison group treatment, controlling for 
baseline P-score and site (CHR + EFEP: F  =  25.32, p 
< .0001; CHR: β = −2.54, SE = 0.86, p = .0034; EFEP: 
β = −8.77, SE = 1.40, p < .0001; see figure 2).
For negative symptoms, FACT was superior to the 
CLR comparison group, at the trend level for the CHR 
subgroup and significantly for the EFEP subgroup, 
Fig. 1. Flow diagram of participant identification, recruitment, and entry into study.
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controlling for baseline P-score and site (CHR + EFEP: 
F = 3.98, p = .02; CHR: β = −1.90, SE = 1.15, p = .099; 
EFEP: β = −4.61, SE = 1.83, p = .012). For disorganized 
and general symptoms, the pattern was similar—signifi-
cant differences for the CHR + EFEP cohort (F = 12.49, 
p < .0001 and F = 6.65, p =  .0015, respectively), with 
significant effects for the EFEP subgroup (β = −3.2345, 
SE = 0.8499, p = .0002 and β = −3.8298, SE = 1.1900, 
p = .0014, respectively) and trend or nonsignificant dif-
ferences for the CHR subgroup (β = −0.6566, SE = 
0.5373, p = .2226 and β = −1.4034, SE = 0.7335, p = 
.0567, respectively; see table 2). Although mean differ-
ences in age, gender, race, and family income between 
treatment groups was in expected directions, further 
adjustment for these variables did not alter the inter-
vention effects. With respect to improvement over time, 
the 4 prodromal symptom domains decreased signifi-
cantly between baseline and 24 months in all 3 groups 
(see table 2 and figure 3).
Conversion, Relapse, and Negative Events
In the CHR subgroup, 6.3% experienced conversion to 
psychosis over 24  months, compared with 2.3% in the 
CLR group. All those in the EFEP subgroup remitted; 
11% subsequently relapsed. The number of conversions 
was too low for a meaningful survival analysis, and a 
chi-squared test was not significant. Twenty-five percent 
of the CHR cohort experienced a first negative event, as 
did 22% in the CLR cohort and 40% in the EFEP group. 
Adjusting for the allocation variable, there was no differ-
ence in the distributions of time to first negative event for 
the CHR group relative to the CLR control group (HR: 
0.94, 95% CI: 0.44–2.04), nor for the EFEP group (HR: 
0.90, 95% CI: 0.25–3.20).
Functional and Global Outcomes
Compared with CLR, FACT had significantly bet-
ter GAF outcomes for the CHR + EFEP cohort, 
Table 1. Baseline Demographic and Clinical Characteristics of the Sample
Comparison (n = 87) Treatment (n = 250)
Statistic pDemographic Characteristics Total (n = 337) CLR (n = 87) CHR (n = 205) EFEP (n = 45)
Age (mean, SD) 16.56 (3.28) 16.23 (3.18) 16.40 (3.30) 17.93 (3.10) F = 4.72 .01
Female, n (%) 134 (40) 26 (30) 89 (43) 19 (42) χ2 = 4.80 .09
Caucasian, n (%) 208 (62) 62 (71) 125 (61) 21 (47) χ2 = 7.70 <.03
African-American, n (%) 31 (9) 5 (6) 16 (8) 10 (22) χ2 = 10.86 < .01
Asian-American, n (%) 13 (4) 4 (5) 9 (4) 0 (0) χ2 = 2.09 .35
Hispanic, n (%) 47 (15) 8 (9) 33 (17) 6 (16) χ2 = 2.66 .27
Married, n (%) 2 (0.6) 1 (0.1) 1 (0.5) 0 (0) χ2 = 0.77 .68
In school/working, n (%) 280 (83) 73 (84) 171 (84) 36 (80) χ2 = 0.40 .82
Income (dollars) 40K–50K 50K–60K 40K–50K 30K–40K F = 3.53 .03
Mother’s age 45.79 (8.11) 46.09 (7.41) 45.96 (8.52) 44.53 (7.45) F = 0.54 .58
Mother’s years education 14.13 (2.53) 14.58 (2.32) 13.91 (2.69) 14.32 (2.06) F = 1.80 .17
Father’s age 49.20 (8.14) 51.16 (7.17) 48.52 (8.59) 47.81 (7.39) F = 1.83 .17
Father’s years education 14.68 (2.10) 14.71 (2.10) 14.76 (2.02) 14.13 (2.41) F = 0.65 .53
SCID-IV diagnoses
 No diagnosis 47 (14%) 19 (22%) 28 (14%) 0 (0%) χ2 = 11.69 <.01
 Any Axis I, current or lifetime 284 (84%) 67 (78%) 173 (86%) 44 (100%) χ2 = 11.69 <.01
 Mood disorder 141 (42%) 32 (37%) 101 (50%) 8 (18%) χ2 = 16.56 <.01
  Bipolar 16 (5%) 2 (2%) 11 (5%) 3 (7%) χ2 = 1.73 .42
  Major depression 114 (34%) 27 (31%) 83 (41%) 4 (9%) χ2 = 17.06 <.01
 Anxiety disorder 120 (36%) 26 (30%) 84 (42%) 10 (23%) χ2 = 7.50 <.03
  PTSD 28 (8%) 1 (1%) 25 (12%) 2 (5%) χ2 = 10.89 <.01
   Obsessive–Compulsive 
Disorder
24 (7%) 3 (3%) 20 (10%) 1 (2%) χ2 = 5.61 <.07
  Generalized anxiety disorder 27 (8%) 5 (6%) 18 (9%) 4 (9%) χ2 = 0.85 .65
 Substance abuse 28 (8%) 8 (9%) 15 (7%) 5 (11%) χ2 = 0.82 .67
 Psychosis 44 (13%) 0 (0%) 3 (1%) 41 (93%) χ2 = 281.2 <.01
 Other 17 (5%) 5 (6%) 10 (5%) 2 (5%) χ2 = 0.12 .94
Psychiatric and medical history
 Prior psychiatric hospitalization 103 (31%) 21 (24%) 52 (26%) 30 (68%) χ2 = 32.97 < .01
 Outpatient counseling 240 (72%) 62 (72%) 152 (75%) 26 (59%) χ2 = 4.48 < .11
 Prior head injury 44 (13%) 9 (10%) 29 (14%) 6 (13%) χ2 = 0.78 .68
 Prior antipsychotic medications 112 (34%) 23 (27%) 63 (31%) 26 (59%) χ2 = 15.32 < .01
Note: The p values derive from 2 degrees of freedom tests. CHR, clinically higher risk; CLR, clinically lower risk; EFEP, early first-episode 
psychosis; PTSD, posttraumatic stress disorder; SCID-IV, Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version IV.
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though not for the subgroups (CHR + EFEP, F = 4.79, 
p = .0091; CHR: β = 1.86, SE = 2.88, p = .517; EFEP: β 
= 8.19, SE = 4.64, p = .079). Unadjusted change scores 
at 24  months for GAF increased significantly in all 
groups, ending at the same level, though change scores 
over 24  months were larger in the FACT-treated sub-
groups (CLR: 60.2 [Δ = 10.65; t = 4.360, df = 53, p < 
.001]; CHR: 59.0 [Δ = 17.47; t = 10.945, df = 131, p < 
.001]; EFEP: 62.4 [Δ = 34.55; t = 10.497, df = 32, p < 
.001]). Adjusting for the allocation variable, GF scores 
for both the EFEP and CHR subgroups did not dif-
fer significantly from CLR (see table  2). Both mean 
GF:Role and GF:Social unadjusted scores increased 
significantly from baseline to 24 months among CHR 
(GF:S: t = 7.143, df = 118, p < .0001; GF:R: t = 2.202, 
df = 118, p = .030) and EFEP (GF:S: t = 3.832, df = 31, 
p  =  .001; GF:R: t  =  2.371, df  =  31, p  =  .024) groups 
but not among the CLR group (ns, nonsignificant). 
The degree of  change was greatest for the EFEP sub-
group (GF:S: CLR, 5.1% vs CHR, 15.3% and EFEP, 
22.3%; GF:R: 0.2% vs 12.1% and 23.6%, respectively; 
see figure 3).
Likewise, adjusting for the allocation variable, QLS 
outcomes for both the EFEP and CHR subgroups did 
not differ significantly from CLR. QLS unadjusted scores 
improved significantly from baseline in the CHR (QLS 
sum score: t  =  7.508, df  =  127, p < .0001) and EFEP 
(t = 3.641, df = 28, p = .001) groups, but not for the CLR 
group (t = 1.402, df = 53, p = .167).
Those in school or working at baseline and 24 months 
were, respectively, 88% and 79% in CLR compared with 
84% and 83% in CHR + EFEP (see table 3).
Between baseline and 24  months, the proportion of 
subjects who increased their level of participation in work 
or school (from neither to one or both or from either to 
both) was 20.6% (35/170) in the CHR + EFEP cohort 
compared with 7.0% (4/57) in the CLR cohort. The OR 
comparing these 2 proportions was significant (OR: 3.44, 
95% CI: 1.16, 11.0, p = .025). Those in school and working 
at baseline and 24 months were, respectively, 11% and 9% 
in CLR compared with 11% and 18% in CHR + EFEP.
Global Outcome
The GTP, incorporating all 10 clinical and functional vari-
ables, demonstrated FACT to be superior to CLR com-
munity treatment (CHR + EFEP: F = 7.50, p =  .0007; 
CHR: β = 0.38, SE = 0.17, p = .024; EFEP: β = 1.0510, 
SE = 0.2787, p = .0002).
Attrition and Site Effects
Though the attrition rate was 34% at 2 years, there 
were no significant differences in baseline measures 
between completers and those with missing data at 
24  months for any of  the 10 outcome measures. The 
attrition rate was 27% at 6 months, 29% at 12 months, 
and 34% at 24 months. At each point, the completion 
Fig. 2. Regression-discontinuity outcome. CLR vs CHR (small arrow), p = .0034. CLR vs EFEP (large arrow), p < .0001. Dashed line 
extending from solid line represents expected regression outcome in the range of CHR and EFEP baseline values, based on CLR values. 
Regression lines are plotted through group averages with parallel slopes estimated from the primary analysis model. Vertical arrow 
lengths approximate effect sizes. CHR, clinically higher risk; CLR, clinically lower risk; EFEP, early first-episode psychosis.
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Fig. 3. Symptom and functional levels across study intervals. CLR, clinically lower risk, baseline n = 87. CHR, clinically higher risk, 
baseline n = 205. EFEP, early first-episode psychosis, baseline n = 45. Data points represent mean raw (unadjusted) scores for each 
subgroup at the respective assessment date.
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rate was lowest for the CLR, higher for the CHR group, 
and highest for the EFEP group (eg, at 12 months, the 
respective percentages were 66%, 71%, and 80%). Site 
was significant as a main effect (F = 4.29 on [5,259] df, 
p  =  .0009). However, there was no significant site by 
group interaction.
Discussion
Summary of Findings
EDIPPP was established to test the effectiveness of early 
identification and intervention with FACT for youth at 
high risk of onset of an initial psychotic episode. Beyond 
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Fig. 3. Continued
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Table 3. Participation in School and Work at Baseline and 24 mo
Group (N)a
In School Only Working Only Both Work and Schoolb Either or Both
Baseline 24 mo Baseline 24 mo Baseline 24 mo Baseline 24 mo
CLR (57)  40 (70%) 30 (53%) 4 (7%) 10 (18%)  6 (11%)  5 (9%)  50 (88%)  45 (79%)
CHR (136)  96 (71%) 78 (57%) 3 (2%) 15 (11%) 16 (12%) 22 (16%) 115 (85%) 115 (85%)
EFEP (34)  23 (68%) 14 (41%) 2 (6%)  4 (12%)  2 (6%)  8 (24%)  27 (79%)  26 (76%)
CHR + EFEP (170) 119 (70%) 92 (54%) 5 (3%) 19 (11%) 18 (11%) 30 (18%) 142 (84%) 141 (83%)
Notes: Entries are frequencies (percentages). Abbreviations are explained in the first footnote to table 1.
aIncludes only subjects with nonmissing school and work status.
b“Both” includes working and in school simultaneously.
testing clinical and functional outcomes in real-world set-
tings, it also intended to assess feasibility of identification 
across whole communities and across a wide spectrum of 
the United States and its diverse populations. The partici-
pating sites educated key professionals in identification 
of early psychosis and provided FACT treatment for 250 
youth. Treatment results included significant effects for 
reduction of positive, negative, disorganized, and gen-
eral symptoms, increases in GAF, and superior overall 
improvement for FACT, compared to community care. 
Over the 24-month period, the FACT group increased 
their level of participation in work or school by 21% 
compared to 7% in the CLR group. Unexpectedly, effects 
for symptoms, GAF, and global outcomes were larger for 
the group having very early psychosis than in the clinical 
high-risk group.
Strengths and Threats to Validity
This study’s strengths include the large and diverse 
sample, independent assessment by reliable raters blind 
to assignment, high fidelity for the key treatment com-
ponent, successful equalization of lower and higher risk 
subsamples in the regression-discontinuity analysis, and 
dissemination of a comprehensive model to 5 other cit-
ies, 2 of which sites’ staff  had no prior experience with 
early psychosis. Caution is warranted because of the 
quasi-experimental design. Although it is considered the 
strongest of the quasi-experimental approaches, other 
possible interpretations of our findings could hold.31 The 
supplementary data contain further discussion of the key 
assumptions underpinning the regression-discontinuity 
analysis and evidence in support of their validity. The 
attrition rate was 27% at 6 months, 29% at 12 months, 
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and 34% at 24 months. There were no significant differ-
ences between completers and noncompleters on any of 
the baseline demographic variables, and the regression 
analyses used data for each subject at any point at which 
they were assessed. Nevertheless, caution is indicated in 
generalizing the results.
Comparison to Other Studies
These results strengthen the evidence that early interven-
tion to prevent onset or progression of psychosis in youth 
is effective, warrants expansion of practice, and constitutes 
an advance for public health. It may alleviate some of the 
ambiguity of results across studies, which has been cited 
as contrary evidence for efficacy.38 More specifically, of the 
trials included in a recent meta-analysis, 3 had single-trial 
significant effects, 2 of which applied PMFG treatment of 
the type used in EDIPPP.5,17,18 This study also strengthens 
the evidence for family intervention in early psychosis, 
continuing a record of efficacy in established schizophre-
nia and first-episode psychosis.39–41 The conversion rate, 
6.3% over 2 years, compares favorably to the 29% found 
in the most recent meta-analysis of untreated naturalistic 
or standard treatment control samples and the 7.6% 1-year 
rate in treated subsamples in randomized controlled trials 
to date.5,22 For studies using the SIPS, the respective rates 
have been 26.4% and 10.3% at 6 or 12 months in 2 RCTs12,42 
and 35% at 30 months in the North American Prodromal 
Longitudinal Study naturalistic follow-up study.43 It sug-
gests that this approach is relevant to the United States, 
because only one of the treatment studies cited was con-
ducted here.5,12
Conclusions
Early identification and intervention with FACT during 
the period prior to onset of frank and lengthy psychosis 
was found to be effective in improving symptoms, GAF, 
and overall outcomes in 6 US cities. The diversity of 
the sample and sites, the scale of the treatment effects, 
and the weight of efficacy evidence from the most recent 
meta-analyses suggests that early intervention, particu-
larly prior to onset of frank psychosis, could lead to 
reduction in total burden of disease.
Supplementary Material
Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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